← Leaderboards
Phyllis C Tien
University Of California San Francisco
$21,664,639
Attributed
$46,419,800
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,128,624 · 11
By mechanism
U01$55,499,356 · 2
R01$8,901,079 · 3
RM1$1,969,877 · 1
P60$1,593,618 · 1
K24$1,488,758 · 1
K23$608,530 · 1
Top collaborators
- Bradley E Aouizerat24 shared
- Jennifer Cohen Price12 shared
- Ruth Martha Greenblatt7 shared
- Andrea A. Kovacs5 shared
- Judith Alissa Hahn1 shared
- Peter W Hunt1 shared
- Jorge R Kizer1 shared
- Elise D Riley1 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Reese T. Jones$7,250,168
- Elise D Riley$16,115,559
- Neal L Benowitz$31,329,042
- Tooru Nemoto$7,267,731
- Peter W Hunt$24,497,989
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanHiv InfectionsCohortResearch PersonnelFibrosisMentorsAgingWomen&AposMorbidity - Disease RateInjuryCareerHepatitis CAreaMetabolicCohort StudiesLeadershipBlood VesselsSan FranciscoPathway InteractionsAnti-Retroviral AgentsPharmaceutical PreparationsPathogenesisImmuneParticipant
Grant awards (57)
SF Bay Area MACS/WIHS Combined Cohort Study$4,444,509
U01 · FY2025 · HL · contact PI
Stimulant and Polysubstance use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE)$1,969,877
RM1 · FY2025 · DA · contact PI
Center for Alcohol/HIV Innovations and Biomarker Research (CALIBER)$1,593,618
P60 · FY2025 · AA
SF Bay Area MACS/WIHS Combined Cohort Study$4,678,523
U01 · FY2024 · HL · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$184,811
K24 · FY2024 · AI · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$4,514,463
U01 · FY2023 · HL · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$184,811
K24 · FY2023 · AI · contact PI
Inter-CFAR Women and HIV Biennial Symposium$31,000
R13 · FY2023 · HD · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$4,486,070
U01 · FY2022 · HL · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$184,811
K24 · FY2022 · AI · contact PI
Proteomic Profiling of Cardiac Dysfunction in the MACS-WIHS Combined Cohort Study$159,619
U01 · FY2022 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$4,701,219
U01 · FY2021 · HL · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$672,140
R01 · FY2021 · DA
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$132,329
K24 · FY2021 · AI · contact PI
Assessing Function and Performance of Population Sexual Orientation and Gender Identity (SOGI) Research Measures in a Racially Diverse HIV-Specific National Cohort$99,777
U01 · FY2021 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$44,725
U01 · FY2021 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$4,303,903
U01 · FY2020 · HL · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$684,441
R01 · FY2020 · DA
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression$682,950
R01 · FY2020 · DK · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$519,977
U01 · FY2020 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$462,848
U01 · FY2020 · HL · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$132,329
K24 · FY2020 · AI · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$105,189
U01 · FY2020 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$64,304
U01 · FY2020 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$3,300,000
U01 · FY2019 · HL · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$1,418,791
U01 · FY2019 · HL · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$694,955
R01 · FY2019 · DA
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression$685,752
R01 · FY2019 · DK · contact PI
SF Bay Area MACS/WIHS Combined Cohort Study$80,233
U01 · FY2019 · HL · contact PI
The Connie Wofsy Women's HIV Study$4,181,287
U01 · FY2018 · AI · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$705,013
R01 · FY2018 · DA
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression$684,328
R01 · FY2018 · DK · contact PI
The Connie Wofsy Women's HIV Study$4,122,513
U01 · FY2017 · AI · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$731,445
R01 · FY2017 · DA
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression$692,364
R01 · FY2017 · DK · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$134,092
K24 · FY2017 · AI · contact PI
The Connie Wofsy Women's HIV Study$4,115,106
U01 · FY2016 · AI
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression$613,493
R01 · FY2016 · DK · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$133,956
K24 · FY2016 · AI · contact PI
The Connie Wofsy Women's HIV Study$3,180,566
U01 · FY2015 · AI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$133,824
K24 · FY2015 · AI · contact PI
The Connie Wofsy Women's HIV Study$3,122,179
U01 · FY2014 · AI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$133,914
K24 · FY2014 · AI · contact PI
The Connie Wofsy Women's HIV Study$42,196
U01 · FY2014 · AI
The Connie Wofsy Women's HIV Study$3,351,359
U01 · FY2013 · AI
Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis$407,297
R01 · FY2013 · AI · contact PI
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health$133,881
K24 · FY2013 · AI · contact PI
Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis$617,477
R01 · FY2012 · AI · contact PI
Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis$540,263
R01 · FY2011 · AI · contact PI
Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis$489,161
R01 · FY2010 · AI · contact PI
Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis$121,770
K23 · FY2009 · AI · contact PI
Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis$121,770
K23 · FY2008 · AI · contact PI
Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis$121,770
K23 · FY2007 · AI · contact PI
Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis$121,770
K23 · FY2006 · AI · contact PI
Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis$121,450
K23 · FY2005 · AI
QUANTIFICATION OF HEPATIC STEATOSIS USING MAGNETIC RESONANCE IMAGING AND MAGNETI$26,937
M01 · FY2005 · RR
HEPATIC STEATOSIS USING MRI &MRS COMPARED TO BIOPSY IN HIV/HCV COINFECTED WOMEN$9,469
M01 · FY2004 · RR